PRJ-13024 is under clinical development by Guangzhou Yinming Biomedical Technology and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase II drugs for Small-Cell Lung Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PRJ-13024’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PRJ-13024 is under development for the treatment of solid tumor, Merkel Cell Carcinoma, Renal Cell Carcinoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Non-Small Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), Head And Neck Cancer Squamous Cell Carcinoma, Gastric Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Melanoma, small-cell lung cancer and Gastroesophageal (GE) Junction Carcinomas.
It acts by targeting hematopoietic progenitor kinase 1 (HPK1). It is administered through oral route.
Guangzhou Yinming Biomedical Technology overview
Guangzhou Yinming Biomedical Technology (MingMed Biotechnology) is a cancer therapy and vision care firm. MingMed Biotechnology is headquartered in Guangzhou, Guangdong, China.
For a complete picture of PRJ-13024’s drug-specific PTSR and LoA scores, buy the report here.